Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1151
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFitzpatrick, Jane-
dc.contributor.authorO'Donnell, John-
dc.contributor.otherBulsara, Max-
dc.contributor.otherZheng, Ming-
dc.contributor.otherMcCrory, Paul Robert-
dc.date.accessioned2017-06-28T02:43:53Z-
dc.date.available2017-06-28T02:43:53Z-
dc.date.issued2017-06-
dc.identifier.citationEpworth Research Institute Research Week 2017; Poster 11: pp 34en_US
dc.identifier.urihttp://hdl.handle.net/11434/1151-
dc.description.abstractIMPORTANCE: Gluteus medius/minimus tendinopathy is a common cause of lateral hip pain or greater trochanteric pain syndrome. OBJECTIVE: There would be no difference in the modified Harris Hip score between a single Platelet-Rich-Plasma (PRP) injection compared to a corticosteroid injection (CSI) in the treatment of gluteal tendinopathy. DESIGN: Randomised Controlled Clinical Trial; Level of evidence 1, recruitment 29 May 2013 to May 2015, follow-up September 2016. Treating/assessing clinicians and subjects were blinded to treatment. PARTICIPANTS: 228 consecutive patients referred with gluteal tendinopathy were screened to enrol 80 participants. 148 excluded (refusal 48, previous surgery 39, sciatica 28, osteoarthritis 17, full thickness tears tendons 17, other 22). INTERVENTION: Subjects were randomised (1:1) to receive either a blinded glucocorticoid or platelet-rich plasma injection intra-tendinously under ultrasound guidance. MAIN OUTCOME MEASURE: A pain and functional assessment was performed using a Modified Harris Hip Score (MHHS) questionnaire at 0, 2, 6 and 12 weeks and patient acceptable symptomatic state (PASS) and minimally important clinical difference (MICD) at 12 weeks. RESULTS: Subjects had a mean age of 60, a ratio of female to male of 9:1 and mean length of symptoms >14 months. Pain and function measured by the mean MHHS showed no difference at 2 weeks CSI 66.95 (SD 15.14) vs PRP 65.23 (SD 11.60) or 6 week CSI 69.51 (SD 14.78) vs PRP 68.79 (SD 13.33). The mean MHHS was significantly improved at 12 weeks PRP 74.05 (SD 13.92) compared to the CSI group with a mean score of 67.13 (SD 16.04, p = 0.048). The PRP group achieved a PASS score of 74 at 12 weeks, reflecting clinical recovery. The proportion of subjects who achieved the MICD of more than 8 points at 12 weeks was 21/37 (56.7%) in the CSI group and 32/39 (82%) in the PRP group (p = 0.016). CONCLUSION: Patients with chronic gluteal tendinopathy >4 months, diagnosed with both clinical and radiological examinations, achieved greater clinical improvement at 12 weeks when treated with a single PRP injection than those treated with a single corticosteroid injection.en_US
dc.subjectPlatelet-Rich Plasma Injectionen_US
dc.subjectPRPen_US
dc.subjectGluteal Tendinopathyen_US
dc.subjectCorticosteroid Injectionen_US
dc.subjectCSIen_US
dc.subjectTreatment Outcomeen_US
dc.subjectLateral Hip Painen_US
dc.subjectTrochanteric Pain Syndromeen_US
dc.subjectGluteus Medius/Minimus Tendinopathyen_US
dc.subjectGlucocorticoiden_US
dc.subjectModified Harris Hip Scoreen_US
dc.subjectMHHSen_US
dc.subjectPatient Acceptable Symptomatic Stateen_US
dc.subjectPASSen_US
dc.subjectMinimally Important Clinical Differenceen_US
dc.subjectMICDen_US
dc.subjectChronic Gluteal Tendinopathyen_US
dc.subjectClinical Improvementen_US
dc.subjectClinical Recoveryen_US
dc.subjectSports Medicineen_US
dc.subjectClinical Effectivenessen_US
dc.subjectMusculoskeletal Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titleThe effectiveness of platelet-rich plasma injections in gluteal tendinopathy - a randomised, double-blind controlled trial comparing a single platelet-rich plasma injection with a single corticosteroid injection.en_US
dc.typeConference Posteren_US
dc.description.affiliatesUniversity of Western Australia, Perth, Australiaen_US
dc.description.affiliatesUniversity of Notre Dame, Perth, Australiaen_US
dc.description.affiliatesUniversity of Melbourne, Parkville, Melbourne, Australiaen_US
dc.type.studyortrialRandomized Controlled Clinical Trialen_US
dc.description.conferencenameEpworth Research Institute Research Week 2017en_US
dc.description.conferencelocationEpworth Research Institute, Victoria, Australiaen_US
dc.type.contenttypeTexten_US
Appears in Collections:Musculoskeletal
Research Month

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.